Results 41 to 50 of about 1,335,871 (234)

Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry. [PDF]

, 2015
Lung cancer is a leading cause of cancer deaths worldwide. Metabolic alterations in tumor cells coupled with systemic indicators of the host response to tumor development have the potential to yield blood profiles with clinical utility for diagnosis and ...
Barupal, Dinesh K, Fiehn, Oliver, Gandara, David R, Hanash, Samir M, Kim, Kyoungmi, Miyamoto, Suzanne, Taguchi, Ayumu, Taylor, Sandra L, Wikoff, William R, Wohlgemuth, Gert, Yoneda, Ken Y   +10 more
core   +2 more sources

Estimating An Optimal Backpropagation Algorithm for Training An ANN with the EGFR Exon 19 Nucleotide Sequence: An Electronic Diagnostic Basis for Non–Small Cell Lung Cancer(NSCLC) [PDF]

, 2011
One of the most common forms of medical malpractices globally is an error in diagnosis. An improper diagnosis occurs when a doctor fails to identify a disease or report a disease when the patient is actually healthy.
Adetiba, E., Daramola, S. A., Ekeh, J.C., Matthews, V. O.   +3 more
core  

Regression of murine lung tumors by the let-7 microRNA. [PDF]

, 2010
MicroRNAs (miRNAs) have recently emerged as an important new class of cellular regulators that control various cellular processes and are implicated in human diseases, including cancer.
Bader, AG, Brown, D, Homer, R, Kelnar, K, Medina, PP, Omotola, M, Ruffino, L, Slack, FJ, Trang, P, Weidhaas, JB, Wiggins, JF   +10 more
core   +2 more sources

Synthetic circRNA therapeutics: innovations, strategies, and future horizons

MedComm
Small molecule drugs are increasingly emerging as innovative and effective treatments for various diseases, with mRNA therapeutics being a notable representative.
Jingsheng Cai, Zonghao Qiu, William Chi‐Shing Cho, Zheng Liu, Shaoyi Chen, Haoran Li, Kezhong Chen, Yun Li, Chijian Zuo, Mantang Qiu   +9 more
doaj   +1 more source

Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity [PDF]

, 2016
BACKGROUND: Lung cancer is the leading cause of cancer related deaths and Malignant Pleural Effusion (MPE) is a frequent complication. Current therapies suffer from lack of efficacy in a great percentage of cases, especially when cancer is diagnosed at ...
CHERUBINI, EMANUELA, DE VITIS, CLAUDIA, Fabiana Fosca Ferrara, Francesca Bergantino, Francesca Fenizia, Gennaro Ciliberto, GIARNIERI, Enrico, GIOVAGNOLI, Maria Rosaria, Luigi Aurisicchio, MANCINI, RITA, MARIOTTA, Salvatore, Matilde Lambiase, Nicola Normanno, NOTO, ALESSIA, RICCI, Alberto, ROSCILLI, GIUSEPPE, Susan Costantini, TORRISI, Maria Rosaria   +17 more
core   +3 more sources

Chinese Expert Consensus on Second-line Treatment for Non-small Cell Lung Cancer with Negative Driver Gene Mutations

Chinese Journal of Lung Cancer
For advanced non-small cell lung cancer (NSCLC) patients with negative driver gene mutations, chemotherapy has always been the standard treatment option, and immune checkpoint inhibitors (ICIs) provide other treatment option for these patients.
Expert Committee on Non-small Cell Lung Cancer of the Chinese Society of Clinical Oncology
doaj   +1 more source

Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.

New England Journal of Medicine, 2023
BACKGROUND Among patients with resectable early-stage non-small-cell lung cancer (NSCLC), a perioperative approach that includes both neoadjuvant and adjuvant immune checkpoint inhibition may provide benefit beyond either approach alone.
H. Wakelee, M. Liberman, T. Kato, M. Tsuboi, Se-Hoon Lee, Shugeng Gao, Keke Chen, C. Dooms, M. Majem, E. Eigendorff, G. Martinengo, O. Bylicki, D. Rodríguez-Abreu, J. Chaft, S. Novello, Jing Yang, S. Keller, A. Samkari, J. Spicer   +18 more
semanticscholar   +1 more source

ANN for Predicting DNA Lung Cancer [PDF]

, 2017
: Lung cancer is the top reason of cancer-associated deaths globally. Surgery is the typical treatment for early-stage non-small cell lung cancer (NSCLC).
Bashhar, Bastami, El-Rabi, Emal, Kashf, Wajeeh Abu, Okasha, Nedal, Sahyoun, Ashraf   +4 more
core  

Validation for revision of the stage IIIA(T1N2) in the forthcoming ninth edition of the TNM classification for lung cancer

BMC Cancer
Objectives The 9th edition of the lung cancer tumor-node-metastasis (TNM) staging system downgrades certain non-small cell lung cancer (NSCLC) patients from stage IIIA (T1N2) to IIB(T1N2a).
Tong Wu, Jingsheng Cai, Yun Li, Rongjing Xie, Kezhong Chen   +4 more
doaj   +1 more source

External validation of pathological T adjustments in the ninth edition of the pleural mesothelioma tumor-node-metastasis classification

Frontiers in Oncology
IntroductionIn the ninth edition pleural mesothelioma (PM) pathological (p) T staging, patients with fissural invasion are upgraded from T1 to T2. This study aimed to externally validate this staging modification.MethodsResected pT1/2 PM patients were ...
Zheng Liu, Zheng Liu, Zheng Liu, Zheng Liu, Jingsheng Cai, Jingsheng Cai, Jingsheng Cai, Jingsheng Cai, Yun Li, Yun Li, Wenhan Weng, Wenhan Weng   +11 more
doaj   +1 more source